ETPrime

Gland Pharma Share Price

  • 1,469.409.11 (0.63%)
  • Volume: 3,33,563
  • Closed
  • Last Updated On: 16 May, 2025, 03:52 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Gland Pharma Share Price
  • 1,469.409.11 (0.63%)
  • Volume: 3,33,563
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

HOLD

Mean Recos by
10 Analysts

2

3

1

0

4

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Gland Pharma share price insights

  • Meeting Agenda: Audited Results & Final Dividend. Please add to watchlist to track closely.

  • Company has spent less than 1% of its operating revenues towards interest expenses and 22.19% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Gland Pharma Ltd. share price moved up by 0.63% from its previous close of Rs 1,460.30. Gland Pharma Ltd. stock last traded price is 1,469.40

    Share PriceValue
    Today/Current/Last1,469.40
    Previous Day1,460.301,458.40

InsightsGland Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		33.52
    EPS - TTM
    (₹)    		42.75
    MCap
    (₹ Cr.)    		23,612.89
    Sectoral MCap Rank
    		22
    PB Ratio
    (x)    		2.71
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month-
    3 Months-
    6 Months-
    1 Year-
    3 Years-
    		-
    VWAP
    (₹)    		1,467.74
    52W H/L
    (₹)
    2,220.95 / 1,277.80

    Gland Pharma Share Price Returns

    1 Day0.63%
    1 Week3.04%
    1 Month1.86%
    3 Months0.69%
    1 Year-17.43%
    3 Years-52.74%
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Gland Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Gland Pharma News & Analysis

    View all Gland Pharma Share News & Announcements

    Gland Pharma Share Recommendations

    Recent Recos

    HOLD

    Current

    Mean Recos by 10 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1970
    • OrganizationMotilal Oswal Securities
    • BUY
    • Target₹2440
    • OrganizationMotilal Oswal Financial Services
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy4444
    Buy----
    Hold1111
    Sell3333
    Strong Sell2222
    # Analysts10101010
    View all Stock Recommendations

    Gland Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 22.19% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income1,442.551,465.491,453.141,579.601,582.55
      Total Income Growth (%)-1.570.85-8.01-0.1910.93
      Total Expenses1,120.421,202.601,229.281,271.411,294.11
      Total Expenses Growth (%)-6.83-2.17-3.31-1.7514.46
      EBIT322.12262.89223.86308.19288.44
      EBIT Growth (%)22.5317.43-27.366.85-2.53
      Profit after Tax (PAT)204.69163.53143.76192.42191.86
      PAT Growth (%)25.1713.75-25.290.29-1.15
      EBIT Margin (%)22.3317.9415.4119.5118.23
      Net Profit Margin (%)14.1911.169.8912.1812.12
      Basic EPS (₹)12.429.938.7311.6811.65
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income1,075.851,120.791,060.511,221.791,141.25
      Total Income Growth (%)-4.015.68-13.207.068.51
      Total Expenses663.41740.81759.29784.56768.70
      Total Expenses Growth (%)-10.45-2.43-3.222.069.22
      EBIT412.44379.99301.23437.22372.55
      EBIT Growth (%)8.5426.15-31.1017.367.06
      Profit after Tax (PAT)295.12281.71222.92321.41276.81
      PAT Growth (%)4.7626.37-30.6416.117.49
      EBIT Margin (%)38.3433.9028.4035.7932.64
      Net Profit Margin (%)27.4325.1321.0226.3124.25
      Basic EPS (₹)17.9117.1013.5319.5116.81
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue5,834.963,865.064,624.653,597.65
      Total Revenue Growth (%)50.97-16.4228.5529.77
      Total Expenses4,702.422,754.023,006.092,262.84
      Total Expenses Growth (%)70.75-8.3932.8527.16
      Profit after Tax (PAT)772.46781.041,211.66996.96
      PAT Growth (%)-1.10-35.5421.5429.00
      Operating Profit Margin (%)20.4530.8536.8938.64
      Net Profit Margin (%)13.6321.5427.5328.79
      Basic EPS (₹)46.9047.4473.8163.07
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue4,334.093,856.994,624.653,597.652,772.41
      Total Revenue Growth (%)12.37-16.6028.5529.7730.17
      Total Expenses2,928.602,752.133,005.612,262.801,779.54
      Total Expenses Growth (%)6.41-8.4332.8327.1625.02
      Profit after Tax (PAT)1,043.33775.831,212.16997.01772.86
      PAT Growth (%)34.48-36.0021.5829.0071.02
      Operating Profit Margin (%)33.9130.7536.9038.6437.97
      Net Profit Margin (%)25.0321.4527.5428.7929.35
      Basic EPS (₹)63.3547.1273.8463.0749.88

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets10,661.258,777.547,833.626,496.08
      Total Assets Growth (%)21.4612.0520.5958.98
      Total Liabilities1,937.40818.81676.00592.84
      Total Liabilities Growth (%)136.6121.1314.0334.80
      Total Equity8,723.847,958.727,157.625,903.24
      Total Equity Growth (%)9.6111.1921.2561.90
      Current Ratio (x)4.049.4610.0510.00
      Total Debt to Equity (x)0.040.000.000.00
      Contingent Liabilities100.73128.46124.5374.70
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets9,541.098,773.187,834.146,496.064,086.04
      Total Assets Growth (%)8.7511.9920.6058.9816.00
      Total Liabilities545.80819.88675.91592.77439.80
      Total Liabilities Growth (%)-33.4321.3014.0334.78-33.41
      Total Equity8,995.297,953.307,158.235,903.293,646.24
      Total Equity Growth (%)13.1011.1121.2661.9027.40
      Current Ratio (x)11.049.4310.0410.007.93
      Total Debt to Equity (x)0.000.000.000.000.00
      Contingent Liabilities100.73128.46124.53219.23134.54

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities996.80363.97790.77604.93
      Net Cash used in Investing Activities-1,756.911,208.19-1,002.62-1,524.00
      Net Cash flow from Financing Activities-799.4214.9234.901,238.46
      Net Cash Flow-1,551.811,590.08-173.64322.97
      Closing Cash & Cash Equivalent357.091,908.90318.82492.46
      Closing Cash & Cash Equivalent Growth (%)-81.29498.74-35.26190.54
      Total Debt/ CFO (x)0.320.010.000.01
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities1,135.97367.89791.29604.93700.94
      Net Cash used in Investing Activities-2,923.921,208.22-1,010.23-1,524.55-766.08
      Net Cash flow from Financing Activities-7.4014.9234.901,238.46-6.87
      Net Cash Flow-1,789.011,594.04-180.73322.42-66.91
      Closing Cash & Cash Equivalent116.211,905.22311.18491.92169.50
      Closing Cash & Cash Equivalent Growth (%)-93.90512.25-36.74190.22-28.30
      Total Debt/ CFO (x)0.000.010.000.010.01

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)8.859.8116.9216.88
      Return on Capital Employed (%)12.5013.8922.3922.36
      Return on Assets (%)7.248.8915.4615.34
      Interest Coverage Ratio (x)57.38169.90330.81392.33
      Asset Turnover Ratio (x)0.580.440.6153.30
      Price to Earnings (x)39.3726.8144.4440.82
      Price to Book (x)3.482.637.506.87
      EV/EBITDA (x)19.1713.5429.1926.12
      EBITDA Margin (%)26.5334.9039.4041.49
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)11.599.7516.9316.8821.19
      Return on Capital Employed (%)15.4813.8222.3922.3626.83
      Return on Assets (%)10.938.8415.4715.3418.91
      Interest Coverage Ratio (x)200.87169.82331.03392.34139.24
      Asset Turnover Ratio (x)0.460.440.6153.3064.44
      Price to Earnings (x)29.1526.9544.4440.82-
      Price to Book (x)3.372.637.506.87-
      EV/EBITDA (x)18.2413.6129.1926.12-
      EBITDA Margin (%)37.8034.8139.4141.4941.56

    Financial InsightsGland Pharma

    • Income (P&L)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 22.19% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Gland Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Gland Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Gland Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Gland Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Gland Pharma Technicals

    • Bullish / Bearish signals for Gland Pharma basis selected technical indicators and moving average crossovers.

      20 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on:

    Gland Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Gland Pharma33.522.718.8512.507.2417.3020.4513.6346.904.040.040.32
          Piramal Pharma312.553.601.126.400.5810.648.340.190.691.540.585.29
          Suven Pharma 98.6213.4314.6419.2413.322.8039.2928.5611.8011.820.020.11
          Syngene Int.51.065.3610.4912.617.3011.6918.6913.6212.351.640.030.10
          J B Chemicals37.368.4319.2124.6915.4316.9222.9416.8342.453.060.000.02
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Wockhardt
          • Eris Lifesciences
          • Emcure Pharmaceuticals Ltd.
          • Neuland Labs
          • Concord Biotech Ltd.

          Choose from Stocks

            See All Parameters

          Peers InsightsGland Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Gland Pharma Shareholding Pattern

            • Loading...
              Showing Gland Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters51.8351.8351.8351.83
              Pledge0.000.000.000.00
              FII6.905.044.476.88
              DII33.2734.8035.3732.83
              Mutual Funds31.1632.3732.8330.53
              Others8.008.338.338.46
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters8,53,93,93451.83 %0.00
              Pledge00.00 %0.00
              FII1,13,75,8576.90 %1.86
              DII5,48,16,46233.27 %-1.52
              MF5,13,40,70431.16 %-1.20
              Others1,31,70,1708.00 %-0.33

            Gland Pharma MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Gland Pharma News Gland Pharma Quarterly Results Gland Pharma Dividend Gland Pharma Q1 ResultsGland Pharma Q2 ResultsGland Pharma Q3 ResultsGland Pharma Q4 Results

            Gland Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 20, 2025May 06, 2025Board MeetingAudited Results & Final Dividend
              Apr 01, 2025Feb 28, 2025POM-
              Mar 11, 2025Feb 07, 2025POM-
              Feb 03, 2025Jan 16, 2025Board MeetingQuarterly Results
              Dec 10, 2024Nov 08, 2024POM-
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final2000%20.0Aug 16, 2024May 22, 2024

            • No other corporate actions details are available.

            About Gland Pharma

            Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 23,612.89 Crore) operating in Pharmaceuticals sector. Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • YK

              Yiu Kwan Stanley Lau

              Chairman & Ind.Director
              SS

              Srinivas Sadu

              Managing Director & CEO
              JA

              Jia Ai (Allen) Zhang

              Non Executive Director
              QC

              Qiyu Chen

              Non Executive Director
              Show More
            • Deloitte Haskins & Sells
              S R Batliboi & Associates LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty 500, BSE 500, Nifty Pharma, + 17 more

            Address

            Sy.No. 143-148, 150 & 151,Near Gandi Maisamma �X� Roads,Hyderabad, Telangana - 500043

            Contact

            investors@glandpharma.com

            https://www.glandpharma.com

            More Details

            FAQs about Gland Pharma share

            • 1. What's Gland Pharma share price today and what are Gland Pharma share returns ?
              Gland Pharma share price is Rs 1,469.40 as on 16 May, 2025, 03:59 PM IST. Gland Pharma share price is up by 0.63% based on previous share price of Rs. 1461.2. In last 1 Month, Gland Pharma share price moved up by 1.86%.
            • 2. What is the CAGR of Gland Pharma?
              The CAGR of Gland Pharma is 13.09.
            • 3. What are the returns for Gland Pharma share?
              Return Performance of Gland Pharma Shares:
              • 1 Week: Gland Pharma share price moved up by 3.04%
              • 1 Month: Gland Pharma share price moved up by 1.86%
            • 4. What is 52 week high/low of Gland Pharma share price?
              In last 52 weeks Gland Pharma share had a high price of Rs 2,220.95 and low price of Rs 1,277.80
            • 5. What is the PE & PB ratio of Gland Pharma?
              The PE ratio of Gland Pharma stands at 34.16, while the PB ratio is 2.76.
            • 6. Who are the key owners of Gland Pharma stock?
              Following are the key changes to Gland Pharma shareholding:
              • Promoter holding has not changed in last 9 months and holds 51.83 stake as on 31 Mar 2025
              • Domestic Institutional Investors holding has gone up from 32.83 (30 Jun 2024) to 33.27 (31 Mar 2025)
              • Foreign Institutional Investors holding has gone up from 6.88 (30 Jun 2024) to 6.9 (31 Mar 2025)
              • Other investor holding have gone down from 8.46 (30 Jun 2024) to 8.0 (31 Mar 2025)
            • 7. What is the market cap of Gland Pharma?
              Market Capitalization of Gland Pharma stock is Rs 23,612.89 Cr.
            • 8. What are the Gland Pharma quarterly results?
              Total Revenue and Earning for Gland Pharma for the year ending 2024-03-31 was Rs 5834.96 Cr and Rs 772.46 Cr on Consolidated basis. Last Quarter 2024-12-31, Gland Pharma reported an income of Rs 1442.55 Cr and profit of Rs 204.69 Cr.
            • 9. How can I quickly analyze Gland Pharma stock?
              Key Metrics for Gland Pharma are:
              • PE Ratio of Gland Pharma is 33.52
              • Price/Sales ratio of Gland Pharma is 5.36
              • Price to Book ratio of Gland Pharma is 2.71
            • 10. Who is the CEO of Gland Pharma?
              Srinivas Sadu is the Managing Director & CEO of Gland Pharma
            • 11. Who's the chairman of Gland Pharma?
              Yiu Kwan Stanley Lau is the Chairman & Ind.Director of Gland Pharma
            • 12. Who are the peers for Gland Pharma in Pharmaceuticals sector?
              Top 10 Peers for Gland Pharma are Concord Biotech Ltd., Emcure Pharmaceuticals Ltd., Natco Pharma Ltd., J B Chemicals & Pharmaceuticals Ltd., Wockhardt Ltd., Suven Pharmaceuticals Ltd., Syngene International Ltd., Eris Lifesciences Ltd., Piramal Pharma Ltd. and Neuland Laboratories Ltd.

            Trending in Markets

            Top Gainers As on 03:59 PM | 16 May 2025

            GRSE2,481.70
            686.70 (38.26%)
            Cochin Shipyard2,035.60
            551.00 (37.11%)
            Apar Industries8,228.00
            2136.00 (35.06%)
            eClerx Services3,301.80
            852.40 (34.80%)
            Kirloskar Oil895.50
            225.65 (33.69%)

            Top Losers As on 03:59 PM | 16 May 2025

            Raymond607.60
            -848.60 (-58.27%)
            Neuland Labs11,056.00
            -1373.00 (-11.05%)
            KPR Mill1,175.90
            -130.35 (-9.98%)
            Chambal Fertilisers632.10
            -61.80 (-8.91%)
            Vijaya Diagnostic909.80
            -83.30 (-8.39%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Gland Pharma Share Price
            The Economic Times
            BrowseCompanies: